Drug Approval | September 09, 2021
Merck’s KEYTRUDA receives China approval for Esophageal cancer
The medicine is now approved for eight indications across five different types of cancer in China.
The medicine is now approved for eight indications across five different types of cancer in China.
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The trial will be conducted across 10 sites in India
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Subscribe To Our Newsletter & Stay Updated
